Equities

Natera Inc

45E:BER

Natera Inc

Actions
  • Price (EUR)160.00
  • Today's Change4.00 / 2.56%
  • Shares traded40.00
  • 1 Year change+223.89%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 15:22 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.

  • Revenue in USD (TTM)1.53bn
  • Net income in USD-214.69m
  • Incorporated2007
  • Employees3.28k
  • Location
    Natera Inc13011 MCCALLEN PASSBUILDING A SUITE 100AUSTIN 78753United StatesUSA
  • Phone+1 (650) 249-9090
  • Fax+1 (302) 674-5266
  • Websitehttps://www.natera.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NTRA:NSQ since
announced
Transaction
value
Invitae Corp-Reproductive Health AssetsDeal completed22 Jan 202422 Jan 2024Deal completed154.00%52.50m
Data delayed at least 15 minutes, as of Nov 21 2024 20:23 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.